RBC Life Sciences, Inc.
RBCL · OTC
12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.03 | -0.27 | -0.16 |
| FCF Yield | 1.01% | -801.33% | -58.49% | 0.79% |
| EV / EBITDA | 3.21 | 2.96 | -46.09 | -28.68 |
| Quality | ||||
| ROIC | -9.96% | -26.43% | -5.17% | -3.82% |
| Gross Margin | 52.82% | 55.25% | 55.32% | 47.16% |
| Cash Conversion Ratio | -0.21 | 5.73 | 1.01 | -0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.04% | -1.47% | 3.96% | -3.62% |
| Free Cash Flow Growth | 100.15% | -163.48% | -6,289.68% | 107.55% |
| Safety | ||||
| Net Debt / EBITDA | 5.85 | 4.79 | 17.30 | 65.96 |
| Interest Coverage | 0.00 | -60.51 | -6.53 | -5.60 |
| Efficiency | ||||
| Inventory Turnover | 2.93 | 2.55 | 2.63 | 2.62 |
| Cash Conversion Cycle | 92.87 | 117.81 | 88.52 | 108.83 |